This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What Makes Prothena (PRTA) a New Buy Stock
by Zacks Equity Research
Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues
by Zacks Equity Research
Prothena (PRTA) records impressive second-quarter earnings as the top line benefits from a $80-million payment from collaboration partner BMY.
Prothena (PRTA) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of 220.79% and 487.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Merus (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Prothena (PRTA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Prothena (PRTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Legend Biotech (LEGN) Surges 12.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Legend Biotech (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
by Zacks Equity Research
Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the disease.
Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?
by Zacks Equity Research
Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?
by Sanghamitra Saha
On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
by Zacks Equity Research
If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
by Zacks Equity Research
Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune
by Zacks Equity Research
Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab
by Kinjel Shah
If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.
Eli Lilly (LLY) Alzheimer's Drug Donanemab Gets FDA Panel Nod
by Zacks Equity Research
Eli Lilly (LLY) Alzheimer's disease drug, donanemab, receives Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) recommendation.
Biogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance
by Zacks Equity Research
FDA accepts Biogen's (BIIB) partner Eisai's sBLA for a maintenance intravenous dosing version of Alzheimer's drug Leqembi. The final FDA decision is expected on Jan 25, 2025.
Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?
by Zacks Equity Research
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
by Zacks Equity Research
Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.
Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses
by Zacks Equity Research
Prothena (PRTA) posts a wider-than-expected loss in the first quarter on lower revenues and higher costs.
Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of -10.74% and 98.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 5.71% and 0.78%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline
by Zacks Equity Research
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
J&J (JNJ) to Begin Pharma Q1 Earnings Season: What's in Store?
by Zacks Equity Research
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug
by Zacks Equity Research
Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.
Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense
by Zacks Equity Research
Prothena (PRTA) posts a wider-than-expected loss in the fourth quarter on lower revenues and higher costs.
Arvinas, Inc. (ARVN) Soars 10.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.